CAPR Quote, Financials, Valuation and Earnings

ClearPoint Neuro has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -71.02%. Capricor Therapeutics's return on equity of -75.99% beat ClearPoint Neuro's return on equity of -73.69%.

Capricor Therapeutics has a consensus price target of $22.90, signalling upside risk potential of 199.74%. On the other hand ClearPoint Neuro has an analysts' consensus of $29.00 which suggests that it could grow by 154.39%. Given that Capricor Therapeutics has higher upside potential than ClearPoint Neuro, analysts believe Capricor Therapeutics is more attractive than ClearPoint Neuro.

Capricor Therapeutics has a beta of 0.820, which suggesting that the stock is 18.02% less volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.296%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than ClearPoint Neuro quarterly revenues of $8.5M. Capricor Therapeutics's net income of -$24.4M is lower than ClearPoint Neuro's net income of -$6M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 13.31x versus 9.76x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -30140.49%. Capricor Therapeutics's return on equity of -75.99% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Capricor Therapeutics has a consensus price target of $22.90, signalling upside risk potential of 199.74%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 451.47%. Given that Inovio Pharmaceuticals has higher upside potential than Capricor Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Capricor Therapeutics.

Capricor Therapeutics has a beta of 0.820, which suggesting that the stock is 18.02% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Capricor Therapeutics's net income of -$24.4M is lower than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 13.31x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of -63.94% compared to Capricor Therapeutics's net margin of -2004.36%. Capricor Therapeutics's return on equity of -75.99% beat Lexicon Pharmaceuticals's return on equity of -90.8%.

Capricor Therapeutics has a consensus price target of $22.90, signalling upside risk potential of 199.74%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $2.58 which suggests that it could grow by 138.89%. Given that Capricor Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Capricor Therapeutics is more attractive than Lexicon Pharmaceuticals.

Capricor Therapeutics has a beta of 0.820, which suggesting that the stock is 18.02% less volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.928%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.3M. Capricor Therapeutics's net income of -$24.4M is higher than Lexicon Pharmaceuticals's net income of -$25.3M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 13.31x versus 12.08x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences has a net margin of -63.94% compared to Capricor Therapeutics's net margin of 1.38%. Capricor Therapeutics's return on equity of -75.99% beat Neurocrine Biosciences's return on equity of 12%.

Capricor Therapeutics has a consensus price target of $22.90, signalling upside risk potential of 199.74%. On the other hand Neurocrine Biosciences has an analysts' consensus of $161.92 which suggests that it could grow by 21.32%. Given that Capricor Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Capricor Therapeutics is more attractive than Neurocrine Biosciences.

Capricor Therapeutics has a beta of 0.820, which suggesting that the stock is 18.02% less volatile than S&P 500. In comparison Neurocrine Biosciences has a beta of 0.243, suggesting its less volatile than the S&P 500 by 75.74%.

Capricor Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics pays -- of its earnings as a dividend. Neurocrine Biosciences pays out -- of its earnings as a dividend.

Capricor Therapeutics quarterly revenues are $11.1M, which are smaller than Neurocrine Biosciences quarterly revenues of $572.6M. Capricor Therapeutics's net income of -$24.4M is lower than Neurocrine Biosciences's net income of $7.9M. Notably, Capricor Therapeutics's price-to-earnings ratio is -- while Neurocrine Biosciences's PE ratio is 45.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics is 13.31x versus 5.72x for Neurocrine Biosciences. Usually stocks with elevated PS ratios are considered overvalued.